Track 1: Pharmacovigilance and its Challenges |
Track 1-1 |
Role of pharmacovigilance in health regulation |
Track 1-2 |
International collaboration and new pharmacovigilance legislation |
Track 1-3 |
Role of pharma industries in the improvement of pharmacovigilance system |
Track 1-4 |
Fatality of pharmacovigilance failure |
Track 1-5 |
Detection & evaluation of drug safety signals |
Track 2: Role of Clinical Trials |
Track 2-1 |
Data collection and quality control |
Track 2-2 |
Alternative trials design and models |
Track 2-3 |
Multi center trials and monitoring |
Track 2-4 |
Practice of good and ethical clinical trials |
Track 3: Clinical Trials on Diseases |
Track 3-1 |
Recent clinical trials on Alzheimer's disease |
Track 3-2 |
Recent clinical trials on Parkinson’s disease |
Track 3-3 |
Clinical trials on cancer |
Track 3-4 |
Applications of biomarkers in clinical trials |
Track 3-5 |
Emerging technology in clinical trials |
Track 4: Adverse Drug Reactions |
Track 4-1 |
Assessing & reporting adverse drug reactions |
Track 4-2 |
Reduction of adverse drug reaction by nano technology |
Track 4-3 |
Expected and un-expected drug reactions and its reporting |
Track 4-4 |
Drugs in human pregnancy and nursing |
Track 4-5 |
Pharmacotherapy and Pharmacogenomics |
Track 4-6 |
Post marketing reports on adverse effects |
Track 5: Drug Interactions |
Track 5-1 |
Advances of pharmacokinetic interactions |
Track 5-2 |
Advances of pharmacodynamic interactions |
Track 5-3 |
Drug and substance abuse |
Track 5-4 |
Drug-drug interactions |
Track 5-5 |
Pharmacoenvironmentology |
Track 6: Pharmacy Practices and Its Challenges |
Track 6-1 |
Pharmacy practice and its guidelines |
Track 6-2 |
Challenges in compounding and dispensing practice |
Track 6-3 |
Drug toxicity and drug safety measures |
Track 6-4 |
Pharmacoepidemiology of drug shortages |
Track 7: Regulatory Affairs |
Track 7-1 |
Role of regulatory affairs in pharmacovigilance |
Track 7-2 |
Role of regulatory agencies in safe medicines and medical devices |
Track 7-3 |
Risk minimization tools |
Track 8: Risk Management: New Approaching Paradigm for
Pharmacovigilance
|
Track 8-1 |
Information technology in Pharmacovigilance and promoting companies |
Track 8-2 |
Review of software’s used in pharmacovigilance and clinical trials |
Track 8-3 |
Risk communication: Interface between pharmacovigilance,
sales and marketing |
Track 8-4 |
Risk management versus recent market withdrawal |
Track 8-5 |
Monitoring unlicensed, off labels and orphan drugs |
Track 9: Clinical Research and Statistics |
Track 9-1 |
Guidelines for clinical research and its statistics |
Track 9-2 |
Advanced Information technology in clinical trials and promoting companies |
Track 9-3 |
Data mining concepts and techniques |
Track 10: Strategies for Growth in Pharma Environment |
Track 10-1 |
Strategic development towards FDA Approval |
Track 10-2 |
Advances in changing pharmacovigilance regulation system |
Track 10-3 |
Post market product surveillances |